<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126567</url>
  </required_header>
  <id_info>
    <org_study_id>F09-113</org_study_id>
    <nct_id>NCT01126567</nct_id>
  </id_info>
  <brief_title>Exploratory Biomarker Study of Cerebrospinal Fluid in Healthy Volunteers</brief_title>
  <official_title>A Study of the Effects of Sampling Rate on Cerebrospinal Fluid (CSF) Biomarker Levels in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the effects of cerebrospinal fluid sampling rate
      on biomarker levels of young, healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Multiple Exploratory Biomarkers</measure>
    <time_frame>Day 1 (at 0, 1, 4, 8, 12, 18, and 24 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Multiple Exploratory Biomarkers</measure>
    <time_frame>Day 1 (at 0, 1.2.3.4.5.6.7.8.9.10,12,14,16,18,20,22,and 24 hours)</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>High Sampling Rate</arm_group_label>
    <description>Samples will be obtained at a high rate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Sampling Rate</arm_group_label>
    <description>Samples will be obtained at a low rate</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sampling Rate</intervention_name>
    <description>Both cohorts will have a lumbar catheter placed and CSF samples will be obtained. The only difference between the two arms will be the sampling rate of CSF. One arm will have a high sampling rate and the other will have a low sampling rate.</description>
    <arm_group_label>High Sampling Rate</arm_group_label>
    <arm_group_label>Low Sampling Rate</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, plasma, cerebrospinal fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age is between 18 and 50 years, inclusive

          -  Judged to be in general good health based on medical history, physical exam, neuro
             exam, vital signs, lab profile and ECG

        Exclusion Criteria:

          -  Positive urine drug screen for drugs of abuse

          -  History of bleeding disorder or deep vein thrombosis

          -  History of migraine or other types of headache more than twice/month, history of
             spinal disc disease or chronic significant low back pain

          -  Use of blood thinning compounds within 10 days of lumbar drain placement

          -  Finding on head CT that contraindicates lumbar puncture

          -  History of spinal surgery

          -  Use of tobacco/nicotine containing products within 6 month period prior to initial
             lumbar drain placement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Lenz, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>May 18, 2010</last_update_submitted>
  <last_update_submitted_qc>May 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Daniel LLano, M.D., PhD, Associate Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Phase 1 Clinical Trials, Cerebrospinal Fluid, Biomarker</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

